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There exists a very large literature suggesting that T cells come in a variety of species
and that without the action of Tregs tumors would seldom survive inhibition by T
cell effectors. We believe that much of the evidence supporting the role of Tregs in
cancer is compatible with a perhaps simpler hypothesis based upon the
demonstration that that small quantities of effector T cells tend to stimulate tumors
while larger quantities of seemingly the same cells are inhibitory (an hormesis-like
effect). This possibility seems to destroy much of the need to postulate a role for T
cell suppressors (Tregs) in cancer, but the exposure of effector T cells to antigen may
convert them into Tregs (Tregs do exist). Furthermore, many other data suggest the
possibility that immune inhibition of cancer could be a laboratory artifact seldom if
ever seen in unmodified nature.The Treg hypothesis
In the cases of both tumor and normal tissues, Foxp3(+)CD25(+)CD4 regulatory T
cells (Tregs) have been thought to be of the essence and are the subject of an extensive
literature. Tregs with other antigenic specificities have been described. The basic ex-
periment upon which much of the entire edifice of the Treg cell in cancer appears to
have been built is described by North as follows: mice grow tumors because the tumor
bearer develops Treg cells that interfere with the T effector cell immune inhibition that
might, in the absence of the Tregs, have largely prevented tumor growth [1]. The gen-
eral Treg thesis is supported by experiments demonstrating that effector T cells often
do not inhibit tumor growth in immunodepressed mice when the latter are restored
with T cells from both immune and tumor-bearing donors. In contrast, immuno-
depressed control animals, restored only with normal immune cells, often do not grow
that same original tumor [1]. Furthermore, if a tumor is highly immunogenic, it can
often be made to regress if the animal is heavily irradiated [2]. This result is supposedly
attributable to the unique sensitivity of the Treg cells to ionizing radiation, leaving the
T effector population relatively intact. The elimination of Tregs by CTLA-4-blocking
antibodies has also demonstrated efficacy in various murine models [3,4].© 2013 Prehn and Prehn; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
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It seems there is a logical alternative explanation for most of the observations that seem
to necessitate the existence of Tregs, an explanation that need not involve Treg cells at
all. The argument we shall now advance does not rule out Tregs, but does, we think,
offer an alternative explanation for many, perhaps all, of the observations that have,
heretofore, been blamed on those pesky Tregs. We shall begin by quoting from the ab-
stract of a paper that appeared in 1972:
“Various numbers of spleen cells from specifically immunized mice were mixed with
constant numbers of target antigenic tumor cells, and were then inoculated
subcutaneously into thymectomized, X-irradiated recipients. Small numbers of admixed
immune spleen cells produced a statistically significant, and reproducible, acceleration
of tumor growth in the inoculum as compared with controls containing either non
immune spleen cells or spleen cells from animals immune to a different, non cross-
reacting tumor. Larger numbers of specifically immune spleen cells, however, produced
inhibition of the admixed tumor’s growth. These data imply that the normal immune
reaction may have a dual function in relation to neoplasia: (i) stimulation of tumor
growth, early in the course of the disease, or whenever the immune reaction is minimal;
(ii) inhibition of tumor growth in other circumstances [5] (Prehn 1972)”.
It should be noted that in this experiment the stimulatory and inhibitory spleen cells
were derived from one and the same population so were qualitatively identical, in con-
trast to the Tregs usually described in various other experiments. The possibility does
persist that the immune cells in the stimulatory and inhibitory populations in the 1972
experiment might not have remained identical after exposure to differing quantities of
antigen [5].
Figure 1, which has been published previously, depicts an idealized version of the results
obtained in [5]. The letters and numerals are only arbitrary aids to facilitate discussion.
Numerous authors have supported these observations [6-11] and it seems there now
can be no rational discussion of tumor immunity without asking, “where on the
immunostimulation curve do the data lie?”. It is not known whether these same obser-
vations apply to immune tolerance to normal tissues and the problems of autoimmun-
ity, but it seems safe to infer that they will have some applicability [12].
Despite the numerous other influences on tumor immune effects that have been
noted in the literature [13], the immune reaction curve (Figure 1) seems to us to be ofFigure 1 Idealized chart of data from [5].
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diated as well as T cell mediated phenomena [12].Blockage of immune versus blockage of non immune inhibition of tumor growth
It has not been determined whether the quantity of immunity as depicted in the figure
should designate cell numbers or, more likely, whether the quantity of immunity should
be measured by the number of and quality of reactive immune sites. When one exam-
ines the apparent action of Tregs in permitting tumor growth, one must ask whether
or not the effect seen is caused by dilution (reduction) of normal effector T cells to
stimulatory levels rather than by the inhibition of the function of the normal effector T
cells by the putative Tregs. It seems that in any situation in which an alteration of
tumor growth is attributed to Tregs, it might as easily be attributed to an alteration in
T effector cell concentration. As an example, the cure of an immunogenic tumor by radi-
ation of the host could be explained by depriving the tumor of necessary lymphoid stimu-
lation by shifting the total effective immune reaction far enough to the left. (According to
this hypothetical scheme, tumors will grow relatively poorly if the immune reaction is
shifted sufficiently far to either the left or to the right - see Figure 1). There is experimen-
tal evidence by one of our students showing that 3-methylcholanthrene-induced mouse
skin papillomas can regress without malignant transformation even when the host animal
had been severely immunodepressed; transformation to malignancy as well as growth may
depend upon a stimulatory level of immune reaction [15,16].
The possibility that effector T cells are turned into effective Tregs by their exposure
to low levels of antigen is an explanation that must not be forgotten. However, some-
what against this idea is the observation that Tregs can sometimes be specific for ele-
ments of the normal tissue in which the tumor had originated rather than for the
tumor per se [17,18]. The possibility exists that Tregs may have been designed by
nature to react with normal (non-tumorous) antigens and might thus be involved in
the prevention of autoimmunity.
It can now be argued that all untransplanted tumors may be continuously stimulated
by an immune response. Inhibitory immunity may be an artifact usually seen only in
transplanted tumors or under conditions in which the immune reaction is in some way
artificially altered. This argument is suggested by the following facts:
(1) It is relatively difficult to induce growth-inhibiting immunity in the autochthonous
mouse to its own native tumor [19].
(2) Cancer progression in the mouse appears to depend upon the immune response [20].
(3) 3-methylcholanthrene-induced mouse skin papillomas apparently fail to transform
to malignancy in the absence of immunity [16];
(4) All cancers appear to possess tumor specific antigens [9],
(5) Human carcinomas tend to “flare” in HIV/AIDS patients during and as a result of
HAART treatment [21,22].
Selective pressure might suffice to keep most reactions near “c” on the immunos-
timulation curve. However, some tumors appear to grow better [23,24] or worse [25]
when the autochthonous patient is immunodepressed; perhaps in these cases the tumors
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to have reached full and stable equilibrium near “c” in Figure 1.Conclusion # 1
We conclude that it is probable that all cancers have tumor specific antigens and in-
deed that they probably could only grow in vivo with great difficulty in the absence of
at least a low level of immune reaction. It may be unnecessary to always postulate the
existence of Tregs inasmuch as immunostimulation by effector T cells seems a simpler
hypothesis and seems to be an adequate explanation for many of the observations upon
which the existence of Tregs appears to depend. However, that effector T cells might
be converted into Tregs by exposure to tumor antigen seems probable [5].Conclusion # 2
The facts suggest that a tumor inhibiting immunity is probably a laboratory artifact sel-
dom, if ever, to be found in unaided nature. However, if one believes in the
Sonnenschein thesis (which we do), growth and mutiplication are the default conditions
of all living cells [26]. Therefore any cell, including a cancerous cell, that fails to grow
is being inhibited by some environmental influence. Untransplanted cancers are usually
and perhaps continuously stimulated rather than inhibited by the “immune” reaction
engendered by them The mechanism of the stimulation could well be an interference
by immune T cells of the tumor inhibition provided by the surrounding normal tissue
environment [27] (see Figure 2).
A possible variation on this theme could be that so-called Tregs might function to
prevent the inhibition of tumor growth by interfering with the antitumor action of the
tumor surround [27,28].Figure 2 Possible scheme for the mechanism of immune-stimulation of tumor growth.
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